Return
Vancomycin-Teixobactin Conjugates
DOI:10.1021/jacs.4c17175.png)
Abstract
En 中文
Vancomycin continues to be a widely used antibiotic of last resort in treating drug-resistant pathogens despite the emergence of vancomycin-resistant strains such as vancomycin-resistant Enterococci (VRE). This communication reports that conjugation of vancomycin to a second antibiotic that targets a different region of lipid II enhances and rescues its antibiotic activity. Conjugation of vancomycin to a minimal teixobactin pharmacophore in which residues 1-6 are replaced with an aromatic amide results in substantial enhancement in activity over the individual components or mixtures thereof. Three conjugates with minimum inhibitory concentrations (MICs) of 0.5 mu g/mL against methicillin-resistant Staphylococcus aureus (MRSA) and 0.063-0.125 mu g/mL against methicillin-susceptible Staphylococcus aureus (MSSA) were identified. Each of these conjugates is also active against VRE, even though the individual components are inactive, with the most active conjugate (Cbp-Lys10-teixo7-11-vanco) having an MIC of 2-4 mu g/mL. These findings demonstrate that conjugation of vancomycin to a minimal teixobactin pharmacophore is an effective strategy for enhancing the activity of vancomycin against important Gram-positive pathogens.
Keywords:
ALA-D-ALA
RESISTANCE
MECHANISM
BINDING
IMPACT
Journal
IF:
15.6
Papers:
20.0W
Citations:
60.2W
Organization
Cited Papers
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
SCIENTIFIC REPORTS
IF3.9
Minimum Inhibitory Concentrations of Vancomycin and Daptomycin Against Methicillin-resistant Staphylococcus Aureus Isolated from Various Clinical Specimens: A Study from South India
Cureus
IF0
The Vancomycin−Nisin(1−12) Hybrid Restores Activity against Vancomycin Resistant Enterococci
Biochemistry
IF0

